Artificial Intelligence (AI) in Drug Discovery Market Growth: Investment Opportunities and Analysis


The Artificial Intelligence (AI) in Drug Discovery Market size was escalated at US$ 722.3 million in 2022, and is projected to reach US$ 11.15 billion by 2030, with a growing CAGR of 40.8% over the forecast period 2023-2030.

Get Free PDF Sample Report:

The field of drug discovery has always been a complex and time-consuming process, requiring extensive research, experimentation, and analysis. However, with the advent of artificial intelligence (AI), there is a tremendous potential to revolutionize this industry.

Artificial intelligence in drug discovery refers to the use of advanced algorithms and machine learning techniques to analyze vast amounts of data and predict the effectiveness of potential drug candidates. This technology has the ability to significantly accelerate the drug discovery process, making it more efficient and cost-effective.

One of the key advantages of AI in drug discovery is its ability to analyze large datasets quickly. With access to massive amounts of genomic data, chemical structures, clinical trial results, and other relevant information, AI algorithms can identify patterns and relationships that humans may overlook. This enables researchers to make more informed decisions about which compounds are most likely to be successful in treating specific diseases.


By Component

  • Software
  • Services

By Technology

  • Machine Learning
  • Deep Learning
  • Supervised Learning
  • Reinforcement Learning
  • Unsupervised Learning
  • Others Technologies

By End-Use

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Centres
  • Academic & Government Institutes

By Application

  • Excavation and mining
  • Immuno-Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Other Applications

Major Players Listed in the Report are as Follows:

IBM Corporation, Microsoft, Google, NVIDIA Corporation, Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, BenevolentAI, Exscientia, Cyclica, BIOAGE, Numerate, NuMedii, Envisagenics, twoXAR, OWKIN, Inc., XtalPi, Verge Genomics, BERG LLC and Other Players.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

Leave a reply